Biotech fund grows investments
Challenger International has confirmed a new investment for its listed biotechnology private equity fund for retail investors, BioTech Capital.
The $3.5 million investment in Brisbane based drug company Xenome is the BioTech fund’s fifth, taking the fund’s total investment across all five investee companies to $14.5 million.
The announcement follows news that existing investee company, X-Ray Technologies, has completed the first sale of its X-Ray Ultra Microscope to NASDAQ listed company FEI.
But even with the latest investment, BioTech Capital has managed to place only 37 per cent of the $40 million raised from investors in August last year, many of them doctors, dentists and other life-sciences professionals.
BioTech Capital executive director Harry Karelis says the fund has considered 116 proposed deals since inception, and has another three currently under review, but only a select few had managed to make it past the fund’s screening process.
“We’ve taken care to seek out quality investments that will prove winners for investors over the medium-long term,” Karelis says.
Karelis says the biotechnology sector, like other asset classes, was not without risk, but would not suffer the same boom bust cycle as dot.com companies.
He says biotechnology, buoyed by the world’s ageing population and a corresponding growth in demand for health services, had the potential to offer significant capital returns for investors.
“Australia has a long track record of achievement in the field of life sciences, and we firmly believe that combining sufficient capital with the right mix of people and technology can result in the expansion of what is currently a nascent industry,” he says.
Recommended for you
The FSCP has announced its latest verdict, suspending an adviser’s registration for failing to comply with his obligations when providing advice to three clients.
Having sold Madison to Infocus earlier this year, Clime has now set up a new financial advice licensee with eight advisers.
With licensees such as Insignia looking to AI for advice efficiencies, they are being urged to write clear AI policies as soon as possible to prevent a “Wild West” of providers being used by their practices.
Iress has revealed the number of clients per adviser that top advice firms serve, as well as how many client meetings they conduct each week.
